title: [Evaluation of low-dose amphotericin B and flucytosine in the treatment of cryptococcal meningitis].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of low-dose amphotericin B (< 0.7 mg x kg(-1) x d(-1)) and flucytosine in patients with non-AIDS-associated cryptococcal meningitis.
  
  
  METHODS
  In non-AIDS patients with cryptococcal meningitis admitted to Huashan Hospital, Fudan University in Shanghai from January 1998 to December 2007, 31 were initially treated with low-dose amphotericin B and flucytosine for more than 1 week. The clinical characteristics, clinical responses, drug-related adverse reactions and outcome of these patients were retrospectively evaluated.
  
  
  RESULTS
  Among the 31 patients enrolled in this study, 8 patients had one or more predisposing factors. Headache, fever, meningeal irritation and vomiting were common clinical symptoms and signs when cryptococcal meningitis was diagnosed. The result of cranial CT scan and/or MRI showed abnormality in 22 cases (78.6%). When the therapy of low-dose amphotericin B and flucytosine ended, the complete response rate was 19.4% (6/31), partial response rate was 54.8% (17/31), and total effective rate was 74.2%. Except for 1 patient lost to follow-up, the 1-year attributable and all-cause mortality among the remaining 30 patients were 0 (0/30) and 10.0% (3/30) respectively. On the other hand, 26 (83.9%) patients had amphotericin B-related adverse reactions, including renal impairment, liver injury, arrhythmia, and anemia, etc. However, most of these reactions were tolerable.
  
  
  CONCLUSIONS
  Low-dose amphotericin B and flucytosine can be used in non-AIDS-associated cryptococcal meningitis with both acceptable efficacy and safety.
authors.affiliation: Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Ji-qin
authors.initials: JQ
authors.lastname: Wu
authors.forename: Xue-ting
authors.initials: XT
authors.lastname: Ou
authors.forename: Yi
authors.initials: Y
authors.lastname: Xie
authors.forename: Yu-xian
authors.initials: YX
authors.lastname: Huang
authors.forename: Wei-min
authors.initials: WM
authors.lastname: Jiang
authors.forename: Jia-lin
authors.initials: JL
authors.lastname: Jin
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Zhu
authors.forename: Xin-hua
authors.initials: XH
authors.lastname: Weng
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy*; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D005437:Flucytosine